suPAR in Surgery

A high preoperative suPAR level is associated with:

  • Post-operative complications
  • Increased mortality risk3
  • Poor prognosis5,6,8-10
  • Postoperative pneumonia7
  • Prosthetic joint infection11

suPAR is a well-studied biomarker predicting prognosis, disease severity, and organ dysfunction and is being considered as a marker of the individual’s inflammatory status. It has been demonstrated that biomarkers are able to improve triage and are effective in identifying high and low-risk patients among acutely admitted patients1. Improving the preoperative risk stratification using biomarkers may optimize the patients’ clinical outcome2. Studies done to date, where suPAR is used for risk stratification, are of observational nature. Most of these studies deal with acute medical and oncological patients.

Gastric surgery patients and orthopedic surgery patients were included in a study conducted in the Emergency Department at Hillerød Hospital, Denmark. The TRIAGE study included 5992 unselected patients and confirmed the prognostic value of suPAR regarding mortality, which was similar in both medical and surgical patients. The same study showed that triage based on the suPAR level was superior to the current triage system in predicting 30-day mortality: AUC 0.84 (0.82-0.87) vs. 0.62 (0.58-0.66), respectively. In multivariate analyses of 30-day mortality in relation to suPAR quartiles, adjusted for sex, age, CRP, leucocytes, and triage category, HR was 1.0, 2.2, 8.3, and 26.9 in the upper quartile3. Of the acute medical patients, 697 had a surgical intervention registered within 3 months after admission. During the 90-day follow-up from surgery, 31 (7.0%) patients died and 158 (35.6%) patients had postoperative complications. After adjusting for age, sex, and ASA classification, the HR for 90-day postoperative mortality was 2.5 (95% CI 1.6-4.0) for every doubling of suPAR level. suPAR was significantly better than CRP at predicting mortality and all complications (P = 0.0036 and P = 0.0041, respectively). Combining ASA classification and suPAR level significantly improved prediction of mortality and the occurrence of a postoperative complication within 90 days after surgery (P < 0.0001)12.

“it is essential to have the help of biomarkers, such as suPAR, which can support the discharge decision”

Juan González del Castillo,
Dr PhD, Hospital Clínico San Carlos, Spain
suPAR News Vol. 1, April 2019

In acute medical patients, elevated suPAR is associated with an increased risk of acute surgery

Acutely admitted medical patients are often fragile and at risk of future surgery. A Danish group investigated if suPAR also predicts acute surgery, which is associated with higher mortality than elective surgery, and if it predicts post-operative mortality13. In a retrospective registry-based cohort study of 17,312 patients, acute surgery was carried out on 2404 patients (13.9%) after a median of 45 days (IQR 5-186) following the index admission. Patients receiving acute surgery had higher baseline suPAR compared with patients receiving elective, or no surgery (p < 0.0001). The hazard ratio (HR) for acute surgery was 1.50 (95% confidence interval (CI): 1.42-1.59) for every doubling of the suPAR level in the adjusted Cox regression analysis. Death within 90 days occurred in 439 (18.3%) patients receiving acute surgery, and the adjusted HR for postoperative mortality was 1.73 (95% CI: 1.52-1.95). The authors conclude that elevated levels of suPAR in acutely admitted medical patients were independently associated with increased risk of future acute surgery as well as with 90-day post-operative mortality13.

A high suPAR level has been demonstrated in both tumor tissue and in blood, and in several cancers, the suPAR level is shown to correlate with a poor prognosis4. In a few studies, suPAR has been studied as a potential biomarker in gastric surgery.

Doctors performing a surgery

In a cohort of 518 elective colorectal cancer patients, preoperative measurement of the suPAR level was performed. In multivariate analyses adjusted for age, sex, tumor classification, and localization, suPAR was significantly associated with mortality, HR 1.74 (1.33-2.26; p<0.0001). In addition, the suPAR level was associated with tumor stage and localization; and in colon cancer patients the suPAR level was significantly higher compared to rectal cancer patients5. The same cohort was also followed in another study, in which the suPAR plasma level was found to be an independent prognostic marker6.

To identify risk patients among elective colon cancer patients the suPAR level was studied. In patients receiving a blood transfusion during surgery, the suPAR level was higher, and a significant association between the suPAR level and posto-perative infections was shown. The occurrence of pneumonia was significantly associated with the suPAR level, but any significant association with other infectious complications could not be found7.

In patients with gastric cancer, the suPAR level was significantly higher compared to healthy controls (2.3 ng/mL ± 0.77), and the suPAR level was significantly higher in cancer patients with metastatic disease (7.0 ng/mL ± 6.1) than in patients with no metastases (4.8 ng/mL ± 4.4). In the group of patients with a suPAR value above 5.2 ng/mL, the mortality was significantly increased8.

In patients with rectal cancer9 and colon cancer10, a similar prognostic value is found, indicating an increased mortality risk.

suPAR in orthopedic surgery

The diagnostic value of suPAR in prosthetic knee/hip joint infection has been examined in a study. The study included 80 patients of which 45 experienced prosthetic joint infection defined by the presence of clinical signs (swelling, redness, tenderness, and pus inside the joint) and a positive culture. In these patients, a significantly higher median suPAR level (6.8 ng/mL) was found compared to patients without infection, who had revision surgery done. Furthermore, suPAR was positively correlated with CRP, and the study showed that suPAR was more precise in diagnosing prosthetic knee/hip joint infection than CRP11.

1. Schuetz P, Hausfater P, Amin A et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. Critical Care (2015) 19:377
2. Biccard BM, Devereaux PJ, Rodseth RN. Cardiac biomarkers in the prediction of risk in the non-cardiac surgery setting. Anaesthesia 2014; 69: 484-493.
3. Østervig RM, Køber L, Forberg JL, Rasmussen LS, Eugen-Olsen J, Iversen K. suPAR—a future prognostic biomarker in emergency medicine. Scand J Trauma Resusc Emerg Med 2015;23(Suppl 1):A31.
4. Kjellman A, Akre O, Gustafsson O et al. Soluble urokinase plasminogen acitvator receptor as a prognostic marker in men participating in prostate cancer screening. J. intern Med. 2011 Mar;269(3):299-305.
5. Lomholt AF, Christensen IJ, Høyer-Hansen G et al. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncology 2010; 49:805-811
6. Stephens RW1, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.J Natl Cancer Inst. 1999 May 19;91(10):869-74.
7. Svendsen MN, Ytting H, Brünner N et al. Preoperative concentrations of suPAR and MBL proteins are associated with the development of pneumonia after elective surgery for colorectal cancer. Surg Infect (Larchmt) 2006 okt;7(5): 463-471.
8. Fidan E, Mentese A, Ozedemir F. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. Med oncol 2013 jun;30(2):540
9. Fernebro E, Madsen RR, Fernö M et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer pateints. Eur j cancer 2000; 486-491.
10. Stephens RW, Nielsen HJ, Christensen IJ. Plasma urokinase recptor levels in patients with colorectal cancer: relationship to prognosis. J natl Cancer Inst 1999, 91, 869-874.
11. Galliera E, Drago L, Marazzi MG. Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker of the prosthetic joint infection: correlation with inflammatory cytokines. Clin Chim Acta 2015 Feb 20;414:23-8.See comment in PubMed Commons below
12. Alstrup M et al. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments. World J Surg. 2019 43(3):780-790
13. Meyer J et a..suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients. Scand J Trauma Resusc Emerg Med. 2018 Feb 1;26(1):11.

Want to know more about suPAR?

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates